Cargando…

Development of a Bamlanivimab Infusion Process in the Emergency Department for Outpatient COVID-19 Patients

The coronavirus disease 2019 (COVID-19) pandemic has prompted the creation of new therapies to help fight against the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Bamlanivimab is a SARS-CoV-2 monoclonal antibody that is administered as an intravenous infusion to ambulatory pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pham, Danny H., Wong, Sandy, Nguyen, Christina T., Lee, Stephen C., Won, Kimberly J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775801/ https://www.ncbi.nlm.nih.gov/pubmed/35052205 http://dx.doi.org/10.3390/healthcare10010042

Ejemplares similares

Bamlanivimab infusion experience at one academic emergency department
por: Yoo, Michael J., et al.
Publicado: (2022)

The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting
por: Corwin, Douglas S, et al.
Publicado: (2021)

506. Outpatient Bamlanivimab, Casirivimab and Imdevimab for COVID-19: Single Center Feasibility Analysis
por: Chundi, Vahini, et al.
Publicado: (2021)

Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process
por: Rubin, Emily B, et al.
Publicado: (2021)

Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection
por: Bavaro, DF, et al.
Publicado: (2022)

500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19
por: Monday, Lea, et al.
Publicado: (2021)

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
por: Dougan, Michael, et al.
Publicado: (2021)

Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19
por: Destras, Grégory, et al.
Publicado: (2021)

BAMLANIVIMAB-INDUCED GUILLAIN-BARRÉ SYNDROME
por: PALAGUACHI, GLADYS, et al.
Publicado: (2021)

Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis
por: Tai, Yu-Lin, et al.
Publicado: (2023)

Bamlanivimab for Mild to Moderate COVID-19 in Kidney Transplant Recipients
por: Jan, Muhammad Y., et al.
Publicado: (2021)

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021)

Bamlanivimab: Guillain-Barre syndrome: case report
Publicado: (2021)

Bamlanivimab: New-onset seizures: case report
Publicado: (2022)

542. Use of Bamlanivimab in Cancer Patients with Mild-to-Moderate COVID-19
por: Brock, Patricia, et al.
Publicado: (2021)

Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report
por: Pillai, Rajapillai L. I., et al.
Publicado: (2023)

Real World Utilization of Bamlanivimab at a Rural Community Hospital
por: Leavitt, Rachael, et al.
Publicado: (2021)

First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19
por: Chen, Peter, et al.
Publicado: (2021)

Bamlanivimab: Gene mutation in COVID-19 infection and off label use: case report
Publicado: (2022)

Use of simulation to develop a COVID-19 resuscitation process in a pediatric emergency department
por: Diaz, Maria Carmen G., et al.
Publicado: (2020)

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany
por: Jensen, Bjoern, et al.
Publicado: (2021)

Current use of intraosseous infusion in Danish emergency departments
por: Molin, Rune, et al.
Publicado: (2010)

BET 3: Peripheral metaraminol infusion in the emergency department
por: Anderson, Kenneth, et al.
Publicado: (2017)

Impact of early versus late administration of bamlanivimab on readmissions in patients with high-risk COVID-19
por: Melton, James D., et al.
Publicado: (2021)

Efficacy of Bamlanivimab in Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural Community
por: Iqbal, Leena, et al.
Publicado: (2021)

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
por: Chew, Kara W., et al.
Publicado: (2022)

PK/PD modeling links accelerated resolution of COVID‐19‐related clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together
por: Ernest, C. Steven, et al.
Publicado: (2022)

Outpatient treatment in women with acute pyelonephritis after visiting emergency department
por: Choi, Hee Kyoung, et al.
Publicado: (2017)

Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis
por: Zuo, Ling, et al.
Publicado: (2022)

Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern
por: Falcone, Marco, et al.
Publicado: (2021)

Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study
por: Kumar, Rebecca N, et al.
Publicado: (2021)

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection
por: Chigutsa, Emmanuel, et al.
Publicado: (2021)

Preferred anatomic site for intraosseous infusion in Danish emergency departments
por: Molin, Rune, et al.
Publicado: (2010)

More Accessible COVID-19 Treatment Through Monoclonal Antibody Infusion in the Emergency Department
por: Heinert, Sara W., et al.
Publicado: (2022)

The use of emergency department and outpatient clinics by Syrian refugees
por: Baykan, Necmi, et al.
Publicado: (2019)

2342: How interruptions affect the triage process in the emergency department
por: Johnson, Kimberly D., et al.
Publicado: (2018)

Bamlanivimab Monoclonal Antibody Treatment in Patients with Graft Versus Host Disease (GVHD) Diagnosed with COVID-19 Infection
por: Faisal, Muhammad Salman, et al.
Publicado: (2022)

Bamlanivimab Reduces ED Returns and Hospitalizations and May Reduce COVID-19 Burden on Low-resource Border Hospitals
por: Quenzer, Faith C., et al.
Publicado: (2022)

Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
por: Chew, Kara W., et al.
Publicado: (2023)

An educational intervention to reduce unjustified peripheral intravenous infusions in the emergency department
por: Noel, Florent, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_au7i6g6bj3kf1aht831q08bprd